Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37088648/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusion: Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.
Share
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37086147/
The role of stimulating glucagon receptors in the treatment of type 2 diabetes and/or obesity is poorly defined and needs to be clarified. Although retatrutide may be superior to the...
Expert Opinion: The role of stimulating glucagon receptors in the treatment of type 2 diabetes and/or obesity is poorly defined and needs to be clarified. Although retatrutide may be superior to the GLP-1 receptor agonist dulaglutide in reducing plasma glucose and body weight, this is not a meaningful comparison, as another GLP-1 receptor...
Share
Semaglutide alleviates inflammation-Induced endothelial progenitor cells injury by inhibiting MiR-155 expression in macrophage exosomes
Source : https://www.sciencedirect.com/science/article/pii/S1567576923005179?via=ihub
Macrophage exosomes impair endothelial progenitor cells function after lipopolysaccharide stimulation. * MiR-155 in macrophage exosomes impairs the function of endothelial progenitor cells and causes inflammation. * Semaglutide may protect endothelial...
Conclusions/Relevance: Semaglutide improved the cell viability of EPCs and also inhibited the expression of inflammatory factors in EPCs as well as miR-155 in exosomes. Semaglutide improves the function and inflammatory status of EPCs may via inhibition of LPS-induced macrophage expression of miR-155 in exosomes.
Share
The Impact of Substantial Improvements in HbA1c and Weight Loss on the Medication Preferences of People with Type 2 Diabetes
The prevalence of diabetes has been increasing worldwide for the past several decades, reaching over 37 million people in the US and approximately five million people in the UK. Over...
Conclusion: HbA1c reduction, frequency of hypoglycemia, and weight reduction are key drivers of preferences among people with T2D when considering medication options. Overall, people with T2D are likely to prefer the tirzepatide over the semaglutide 1mg medication profiles.
Share
Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37047163/
The study aimed to perform a systematic review and meta-analysis of the evidence for the prevention of future cancers following bariatric surgery. A systematic literature search of the Cochrane Library,...
Conclusions/Relevance: Bariatric surgery results in long-term weight loss in morbidly obese patients and improves metabolic syndrome. Bariatric surgery may decrease future overall cancer incidence and mortality, including the incidence of seven obesity-related cancers.
Share